collection
https://read.qxmd.com/read/26338208/management-of-dermatologic-complications-of-lung-cancer-therapies
#21
REVIEW
Silvina B Pugliese, Joel W Neal, Bernice Y Kwong
In recent years, oncogene-directed targeted agents and immunotherapies have expanded the treatment armamentarium for advanced lung cancer and, in particular, non-small cell lung cancer (NSCLC). Along with extended survival, these agents are accompanied by a host of cutaneous complications that affect the skin, hair, and nails. These skin complications range from the well-characterized papulopustular (acneiform) eruption of the epidermal growth factor receptor (EGFR) inhibitors to the emerging characterization of lichenoid skin eruptions seen during treatment with antibodies targeting the programmed cell death protein 1 (PD-1) and programmed cell death protein 1 ligand (PD-L1)...
October 2015: Current Treatment Options in Oncology
https://read.qxmd.com/read/26310719/advances-in-molecular-based-personalized-non-small-cell-lung-cancer-therapy-targeting-epidermal-growth-factor-receptor-and-mechanisms-of-resistance
#22
REVIEW
Robert M Jotte, David R Spigel
Molecularly targeted therapies, directed against the features of a given tumor, have allowed for a personalized approach to the treatment of advanced non-small-cell lung cancer (NSCLC). The reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib had undergone turbulent clinical development until it was discovered that these agents have preferential activity in patients with NSCLC harboring activating EGFR mutations. Since then, a number of phase 3 clinical trials have collectively shown that EGFR-TKI monotherapy is more effective than combination chemotherapy as first-line therapy for EGFR mutation-positive advanced NSCLC...
November 2015: Cancer Medicine
https://read.qxmd.com/read/26332764/clinical-features-and-gene-mutations-of-lung-cancer-patients-30-years-of-age-or-younger
#23
JOURNAL ARTICLE
Yuehong Wang, Junjun Chen, Wei Ding, Bing Yan, Qiqi Gao, Jianying Zhou
PURPOSE: Few studies examining the clinical features and gene mutations in lung cancer patients 30 years of age or younger have been published. A trend towards increasing morbidity has been noted in young patients; thus, an urgent need exists to explore this subgroup of patients. METHODS: Patients aged ≤30 years with pathologically diagnosed lung cancer were retrospectively evaluated. We reviewed the clinical features, gene mutations and prognosis of each patient...
2015: PloS One
https://read.qxmd.com/read/25429239/prevalence-and-natural-history-of-alk-positive-non-small-cell-lung-cancer-and-the-clinical-impact-of-targeted-therapy-with-alk-inhibitors
#24
REVIEW
Puey Ling Chia, Paul Mitchell, Alexander Dobrovic, Thomas John
Improved understanding of molecular drivers of carcinogenesis has led to significant progress in the management of lung cancer. Patients with non-small-cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangements constitute about 4%-5% of all NSCLC patients. ALK+ NSCLC cells respond well to small molecule ALK inhibitors such as crizotinib; however, resistance invariably develops after several months of treatment. There are now several newer ALK inhibitors, with the next generation of agents targeting resistance mutations...
2014: Clinical Epidemiology
https://read.qxmd.com/read/26122186/lung-cancer-squiring-immunotherapy-to-checkmate
#25
COMMENT
Lisa Hutchinson
No abstract text is available yet for this article.
August 2015: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/24715074/epidermal-growth-factor-receptor-tyrosine-kinase-inhibitors-vs-conventional-chemotherapy-in-non-small-cell-lung-cancer-harboring-wild-type-epidermal-growth-factor-receptor-a-meta-analysis
#26
COMPARATIVE STUDY
June-Koo Lee, Seokyung Hahn, Dong-Wan Kim, Koung Jin Suh, Bhumsuk Keam, Tae Min Kim, Se-Hoon Lee, Dae Seog Heo
IMPORTANCE: Current guidelines recommend both epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and cytotoxic chemotherapy drugs as standard treatment options for patients with wild-type (WT) EGFR who were previously treated for non-small cell lung cancer (NSCLC). However, it is not clear that EGFR TKIs are as efficacious as chemotherapy in patients with WT EGFR. OBJECTIVE: To determine the association between first-generation EGFR TKI vs chemotherapy and survival in advanced NSCLC patients with WT EGFR...
April 9, 2014: JAMA
https://read.qxmd.com/read/26063687/experience-with-erlotinib-in-the-treatment-of-non-small-cell-lung-cancer
#27
REVIEW
Lorenza Landi, Federico Cappuzzo
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related deaths. In the last decade, the epidermal growth factor receptor (EGFR) signalling pathway has emerged as one of the most important molecular aberrations, representing an attractive therapeutic target in NSCLC. Drugs interfering with the tyrosine kinase domain of the EGFR (EGFR TKIs), such as erlotinib and gefitinib, have demonstrated efficacy in patients with advanced NSCLC irrespective of therapy line and particularly in patients harbouring activating mutations in the EGFR gene (EGFR(mut+))...
August 2015: Therapeutic Advances in Respiratory Disease
https://read.qxmd.com/read/26051236/clinical-activity-of-afatinib-in-patients-with-advanced-non-small-cell-lung-cancer-harbouring-uncommon-egfr-mutations-a-combined-post-hoc-analysis-of-lux-lung-2-lux-lung-3-and-lux-lung-6
#28
RANDOMIZED CONTROLLED TRIAL
James C-H Yang, Lecia V Sequist, Sarayut Lucien Geater, Chun-Ming Tsai, Tony Shu Kam Mok, Martin Schuler, Nobuyuki Yamamoto, Chong-Jen Yu, Sai-Hong I Ou, Caicun Zhou, Daniel Massey, Victoria Zazulina, Yi-Long Wu
BACKGROUND: Most patients with non-small-cell lung cancer tumours that have EGFR mutations have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21, or both (ie, common mutations). However, a subset of patients (10%) with mutations in EGFR have tumours that harbour uncommon mutations. There is a paucity of data regarding the sensitivity of these tumours to EGFR inhibitors. Here we present data for the activity of afatinib in patients with advanced non-small-cell lung cancer that have tumours harbouring uncommon EGFR mutations...
July 2015: Lancet Oncology
https://read.qxmd.com/read/26045341/anti-egfr-monoclonal-antibodies-in-lung-cancer-treatment
#29
COMMENT
Joan H Schiller
No abstract text is available yet for this article.
July 2015: Lancet Oncology
https://read.qxmd.com/read/26033830/randomized-phase-2-trial-of-erlotinib-in-combination-with-high-dose-celecoxib-or-placebo-in-patients-with-advanced-non-small-cell-lung-cancer
#30
RANDOMIZED CONTROLLED TRIAL
Karen L Reckamp, Marianna Koczywas, Mihaela C Cristea, Jonathan E Dowell, He-Jing Wang, Brian K Gardner, Ginger L Milne, Robert A Figlin, Michael C Fishbein, Robert M Elashoff, Steven M Dubinett
BACKGROUND: Cyclooxygenase 2 (COX-2)-dependent signaling represents a potential mechanism of resistance to therapy with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. This is mediated in part through an EGFR-independent activation of mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (Erk) by prostaglandin E2 (PGE2). PGE2 promotes downregulation of E cadherin and epithelial to mesenchymal transition. The current study investigated EGFR and COX-2 inhibition in patients with non-small cell lung cancer (NSCLC) and elevated baseline urinary metabolite of PGE2 (PGEM)...
September 15, 2015: Cancer
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.